



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

November 10, 2010

Douglas C. MacLellan
President and Chief Executive Officer
Radiant Pharmaceuticals Corporation
2492 Walnut Avenue, Suite 100
Tustin, CA 92780-7039

**Re: Radiant Pharmaceuticals Corporation
Schedule 14A Filed February 1, 2010, as amended
Form 10-K for the Fiscal Year Ended December 31, 2008
Form 10-Q for the Quarter Ended September 30, 2009
Form 10-K for the Fiscal Year Ended December 31, 2009
Form 10-Q for the Quarter Ended March 31, 2010
Form 10-Q for the Quarter Ended June 30, 2010
File No. 001-16695**

Dear Mr. MacLellan:

We have completed our review of your above-referenced filings and do not have any further comments at this time.

Sincerely,

Jeffrey Riedler
Assistant Director

cc: Rachel Schmierer
Leser, Hunter, Taubman & Taubman
17 State Street, Suite 1610
New York, New York 10004